Home NDC 83787-103 ZELSUVMI
Product NDC 83787-103
11-digit product format 837870103
Labeler code 83787
Product ID 83787-103_0af12ae7-bb37-4319-94d1-8074b39d4e1b
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name berdazimer
Dosage form KIT
Labeler LNHC, Inc.
Application NDA217424
Marketing category NDA
Marketing start 2025-04-04
NDC exclude flag No
Listing certified through 2026-12-31
Current FDA listing Yes Source provenance: Browse the complete Orange Book source catalog · source snapshot 43 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N217424-001 ZELSUVMI BERDAZIMER SODIUM EQ 10.3% BASE GEL / TOPICAL RLD, RS 2024-01-05
Orange Book patents# Current patent rows page 1 of 1 · 22 matching rows.
Orange Book exclusivity# Current exclusivity rows page 1 of 1 · 1 matching rows.
Application-product, Exclusivity code, Expiration table Application-product Exclusivity code Expiration N217424-001 NCE 2029-01-05
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-09-14 22:38:34 2026-08 N217424-001 ZELSUVMI EQ 10.3% BASE GEL / TOPICAL RLD, RS 2024-01-05 84e616aacf4f…2026-08-18 06:07:40 2026-07 N217424-001 ZELSUVMI EQ 10.3% BASE GEL / TOPICAL RLD, RS 2024-01-05 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N217424-001 ZELSUVMI EQ 10.3% BASE GEL / TOPICAL RLD, RS 2024-01-05 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N217424-001 ZELSUVMI EQ 10.3% BASE GEL / TOPICAL RLD, RS 2024-01-05 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N217424-001 ZELSUVMI EQ 10.3% BASE GEL / TOPICAL RLD, RS 2024-01-05 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N217424-001 ZELSUVMI EQ 10.3% BASE GEL / TOPICAL RLD, RS 2024-01-05 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N217424-001 ZELSUVMI EQ 10.3% BASE GEL / TOPICAL RLD, RS 2024-01-05 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N217424-001 ZELSUVMI EQ 10.3% BASE GEL / TOPICAL RLD, RS 2024-01-05 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N217424-001 ZELSUVMI EQ 10.3% BASE GEL / TOPICAL RLD, RS 2024-01-05 2680178bc6a6…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N217424-001 ZELSUVMI EQ 10.3% BASE GEL / TOPICAL RLD, RS 2024-01-05 5bbf6a4d5a75…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N217424-001 ZELSUVMI EQ 10.3% BASE GEL / TOPICAL RLD, RS 2024-01-05 d8e5a09893c0…2024-10-29 15:01 UTC 2024-10 N217424-001 ZELSUVMI EQ 10.3% BASE GEL / TOPICAL RLD, RS 2024-01-05 d06236e962d9…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N217424-001 ZELSUVMI EQ 10.3% BASE GEL / TOPICAL RLD, RS 2024-01-05 79d66fd596c7…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 N217424-001 ZELSUVMI EQ 10.3% BASE GEL / TOPICAL RLD, RS 2024-01-05 301d65b070ca…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 N217424-001 ZELSUVMI EQ 10.3% BASE GEL / TOPICAL RLD, RS 2024-01-05 1e350fbaab3a…2024-05-31 18:47 UTC 2024-05 N217424-001 ZELSUVMI EQ 10.3% BASE GEL / TOPICAL RLD, RS 2024-01-05 8072bd15b7f6…2024-03-16 18:09 UTC · 4 captures of this ZIP 2024-03 N217424-001 ZELSUVMI EQ 10.3% BASE GEL / TOPICAL RLD, RS 2024-01-05 6a51e52b5d6a…2024-02-18 07:12 UTC 2024-02 N217424-001 ZELSUVMI EQ 10.3% BASE GEL / TOPICAL RLD, RS 2024-01-05 1c564ffb4f44…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N217424-001 ZELSUVMI EQ 10.3% BASE GEL / TOPICAL RLD, RS 2024-01-05 a50c72e98297…
Observed Orange Book patent history# Patent history page 1 of 11 · 402 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-09-14 22:38:34 2026-08 N217424-001 8282967 2026-05-30 Drug substance 2024-02-02 84e616aacf4f…2026-09-14 22:38:34 2026-08 N217424-001 8956658 2026-05-30 Drug substance 2024-02-02 84e616aacf4f…2026-09-14 22:38:34 2026-08 N217424-001 10376538 2030-08-20 Drug product 2024-02-02 84e616aacf4f…2026-09-14 22:38:34 2026-08 N217424-001 9737561 2030-08-20 U-3802 2024-02-02 84e616aacf4f…2026-09-14 22:38:34 2026-08 N217424-001 9526738 2031-09-03 Drug product 2024-02-02 84e616aacf4f…2026-09-14 22:38:34 2026-08 N217424-001 10265334 2032-07-03 Drug product 2024-02-02 84e616aacf4f…2026-09-14 22:38:34 2026-08 N217424-001 9289442 2032-07-03 U-3803 Drug product 2024-02-02 84e616aacf4f…2026-09-14 22:38:34 2026-08 N217424-001 9855211 2034-02-27 U-3800 Drug product 2024-02-02 84e616aacf4f…2026-09-14 22:38:34 2026-08 N217424-001 9855211 2034-02-27 U-3801 Drug product 2024-02-02 84e616aacf4f…2026-09-14 22:38:34 2026-08 N217424-001 11285098 2034-02-28 Drug product 2024-02-02 84e616aacf4f…2026-09-14 22:38:34 2026-08 N217424-001 10258564 2034-11-22 U-3797 2024-02-02 84e616aacf4f…2026-09-14 22:38:34 2026-08 N217424-001 10258564 2034-11-22 U-3798 2024-02-02 84e616aacf4f…2026-09-14 22:38:34 2026-08 N217424-001 10258564 2034-11-22 U-3799 2024-02-02 84e616aacf4f…2026-09-14 22:38:34 2026-08 N217424-001 10322081 2035-07-10 U-3793 2024-02-02 84e616aacf4f…2026-09-14 22:38:34 2026-08 N217424-001 10322081 2035-07-10 U-3794 2024-02-02 84e616aacf4f…2026-09-14 22:38:34 2026-08 N217424-001 10322081 2035-07-10 U-3795 2024-02-02 84e616aacf4f…2026-09-14 22:38:34 2026-08 N217424-001 10322081 2035-07-10 U-3796 2024-02-02 84e616aacf4f…2026-09-14 22:38:34 2026-08 N217424-001 10736839 2035-07-10 U-3790 2024-02-02 84e616aacf4f…2026-09-14 22:38:34 2026-08 N217424-001 10736839 2035-07-10 U-3791 2024-02-02 84e616aacf4f…2026-09-14 22:38:34 2026-08 N217424-001 10736839 2035-07-10 U-3792 2024-02-02 84e616aacf4f…2026-09-14 22:38:34 2026-08 N217424-001 11040006 2035-07-10 U-3789 Drug product 2024-02-02 84e616aacf4f…2026-09-14 22:38:34 2026-08 N217424-001 11723858 2035-07-10 U-3788 Drug product 2024-02-02 84e616aacf4f…2026-08-18 06:07:40 2026-07 N217424-001 8282967 2026-05-30 Drug substance 2024-02-02 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N217424-001 8956658 2026-05-30 Drug substance 2024-02-02 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N217424-001 10376538 2030-08-20 Drug product 2024-02-02 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N217424-001 9737561 2030-08-20 U-3802 2024-02-02 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N217424-001 9526738 2031-09-03 Drug product 2024-02-02 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N217424-001 10265334 2032-07-03 Drug product 2024-02-02 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N217424-001 9289442 2032-07-03 U-3803 Drug product 2024-02-02 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N217424-001 9855211 2034-02-27 U-3800 Drug product 2024-02-02 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N217424-001 9855211 2034-02-27 U-3801 Drug product 2024-02-02 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N217424-001 11285098 2034-02-28 Drug product 2024-02-02 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N217424-001 10258564 2034-11-22 U-3797 2024-02-02 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N217424-001 10258564 2034-11-22 U-3798 2024-02-02 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N217424-001 10258564 2034-11-22 U-3799 2024-02-02 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N217424-001 10322081 2035-07-10 U-3793 2024-02-02 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N217424-001 10322081 2035-07-10 U-3794 2024-02-02 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N217424-001 10322081 2035-07-10 U-3795 2024-02-02 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N217424-001 10322081 2035-07-10 U-3796 2024-02-02 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N217424-001 10736839 2035-07-10 U-3790 2024-02-02 caaa826d4ba7…
Observed Orange Book exclusivity history# Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
Finished product Yes
Brand name base ZELSUVMI
Listing expiration 2026-12-31 Harmonized RxCUI identifiers# RxCUI identifiers page 1 of 1 · 2 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 2710438 Internal RxNorm lookup 2710443 Internal RxNorm lookup
Harmonized SPL set identifiers# SPL set identifiers page 1 of 1 · 1 matching rows.
DailyMed Package Descriptions# Package NDC, Product, Description table Package NDC Product Description Form Quantity Strength SPL version 83787-103-31 ZELSUVMI 1 in 1 KIT KIT 1 3
DailyMed Dashboard NDC Coverage# NDC, Dashboard title, SPL version table NDC Dashboard title SPL version Validation Dashboard ZIP 83787-103 ZELSUVMI (BERDAZIMER) KIT [LNHC, INC.] 2 Current NDC, 1 package rows 20250406_76b17622-bdb9-41ea-b962-c2acc0df71f7.zip
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
DailyMed RxNorm Mappings# Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Units Marketing start Sample Exclude flag Status 83787-103-31 83787010331 1 KIT in 1 KIT (83787-103-31) * 1 TUBE in 1 CARTON / 17 g in 1 TUBE * 1 TUBE in 1 CARTON / 14 g in 1 TUBE (83787-113-14) 1 kit 2025-04-04 No No Current